Granahan Investment Management LLC Purchases Shares of 122,767 ChemoCentryx, Inc. (NASDAQ:CCXI)
Granahan Investment Management LLC Purchases Shares of 122,767 ChemoCentryx, Inc. (NASDAQ:CCXI)
Granahan Investment Management LLC purchased a new stake in shares of ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 122,767 shares of the biopharmaceutical company's stock, valued at approximately $3,078,000. Granahan Investment Management LLC owned 0.18% of ChemoCentryx at the end of the most recent reporting period.
根据Granahan Investment Management LLC提交给美国证券交易委员会(SEC)的最新13F文件,该公司在第一季度购买了ChemoCentryx,Inc.(纳斯达克代码:CCXI-GET Rating)的新股份。该机构投资者购买了这家生物制药公司的122,767股股票,价值约3,078,000美元。在最近的报告期结束时,Granahan Investment Management LLC拥有ChemoCentryx 0.18%的股份。
A number of other hedge funds also recently bought and sold shares of CCXI. Pictet Asset Management SA acquired a new position in shares of ChemoCentryx during the fourth quarter valued at about $58,453,000. Millennium Management LLC raised its position in shares of ChemoCentryx by 1,663.6% during the fourth quarter. Millennium Management LLC now owns 1,228,224 shares of the biopharmaceutical company's stock valued at $44,720,000 after buying an additional 1,306,776 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of ChemoCentryx during the fourth quarter valued at about $30,184,000. Sofinnova Investments Inc. raised its position in ChemoCentryx by 6,040.6% in the fourth quarter. Sofinnova Investments Inc. now owns 731,222 shares of the biopharmaceutical company's stock worth $26,624,000 after purchasing an additional 719,314 shares in the last quarter. Finally, GW&K Investment Management LLC acquired a new position in ChemoCentryx in the fourth quarter worth about $23,746,000. 81.09% of the stock is currently owned by institutional investors.
其他一些对冲基金最近也买卖了CCXI的股票。Pictet Asset Management SA在第四季度收购了ChemoCentryx股票的新头寸,价值约58,453,000美元。千禧管理公司在第四季度将其在ChemoCentryx股票中的头寸增加了1663.6%。Millennium Management LLC现在拥有这家生物制药公司1,228,224股股票,价值44,720,000美元,上个季度又购买了1,306,776股。马歇尔·华斯有限责任公司在第四季度收购了ChemoCentryx股票的新头寸,价值约30,184,000美元。Sofinnova Investments Inc.在第四季度将其在ChemoCentryx的持仓增加了6,040.6%。Sofinnova Investments Inc.现在持有这家生物制药公司731,222股股票,价值26,624,000美元,上个季度又购买了719,314股。最后,GW&K Investment Management LLC在第四季度收购了ChemoCentryx的一个新头寸,价值约23,746,000美元。81.09%的股票目前由机构投资者持有。
Insider Activity
内幕活动
In other news, CEO Thomas J. Schall sold 130,000 shares of the stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $50.24, for a total transaction of $6,531,200.00. Following the sale, the chief executive officer now directly owns 2,393,352 shares of the company's stock, valued at $120,242,004.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Thomas J. Schall sold 130,000 shares of the stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $50.24, for a total transaction of $6,531,200.00. Following the sale, the chief executive officer now directly owns 2,393,352 shares of the company's stock, valued at $120,242,004.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Susan M. Kanaya sold 46,298 shares of the firm's stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $50.17, for a total transaction of $2,322,770.66. Following the completion of the transaction, the chief financial officer now directly owns 91,317 shares in the company, valued at $4,581,373.89. The disclosure for this sale can be found here. Insiders have sold 213,760 shares of company stock valued at $10,749,838 over the last three months. 8.30% of the stock is owned by insiders.
在其他消息方面,首席执行官托马斯·J·舒尔在8月4日(星期四)的一笔交易中出售了13万股该公司股票。这些股票以50.24美元的平均价格出售,总成交金额为6,531,200.00美元。出售后,首席执行官现在直接拥有2393,352股公司股票,价值120,242,004.48美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过美国证券交易委员会网站获得。在其他消息方面,首席执行官托马斯·J·舒尔在8月4日(星期四)的一笔交易中出售了13万股该公司股票。这些股票以50.24美元的平均价格出售,总成交金额为6,531,200.00美元。出售后,首席执行官现在直接拥有2393,352股公司股票,价值120,242,004.48美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过美国证券交易委员会网站获得。此外,首席财务官Susan M.Kanaya在8月4日(星期四)的一次交易中出售了46,298股该公司的股票。这些股票的平均价格为50.17美元,总成交额为2,322,770.66美元。交易完成后,首席财务官现在直接拥有该公司91,317股,价值4,581,373.89美元。此次拍卖的披露信息可在此处找到。在过去的三个月里,内部人士已经出售了213,760股公司股票,价值10,749,838美元。8.30%的股份由内部人士持有。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
ChemoCentryx Price Performance
ChemoCentryx性价比
CCXI opened at $51.49 on Monday. ChemoCentryx, Inc. has a one year low of $14.95 and a one year high of $51.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.54 and a quick ratio of 4.47. The company's 50 day simple moving average is $38.44 and its 200-day simple moving average is $28.43. The stock has a market capitalization of $3.67 billion, a P/E ratio of -27.24 and a beta of 1.25.
CCXI周一开盘报51.49美元。ChemoCentryx,Inc.的一年低点为14.95美元,一年高位为51.78美元。该公司的债务权益比为0.02,流动比率为4.54,速动比率为4.47。该公司的50日简单移动均线切入位在38.44美元,200日简单移动均线切入位在28.43美元。该股市值为36.7亿美元,市盈率为-27.24,贝塔系数为1.25。
ChemoCentryx Company Profile
ChemoCentryx公司简介
(Get Rating)
(获取评级)
ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
ChemoCentryx,Inc.是一家生物制药公司,专注于在美国开发和商业化治疗炎症性疾病、自身免疫性疾病和癌症的新药。它提供TAVNEOS(Avacopan),一种口服的选择性C5aR抑制剂,用于治疗严重的抗中性粒细胞胞浆抗体相关小血管炎的成人患者。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on ChemoCentryx (CCXI)
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here's Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- 免费获取StockNews.com关于ChemoCentryx(CCXI)的研究报告
- 电子艺界能扭转电子游戏市场的低迷吗?
- 美元将军是美国小池塘里的大鱼。
- 以下是CPI报告将决定市场底部的原因
- MarketBeat:回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.
接受ChemoCentryx日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对ChemoCentryx和相关公司的最新新闻和分析师评级的每日简要摘要。